lauflumide (NLS-4) / NLS Pharma - LARVOL DELTA

Effects of NLS-4 (Lauflumide) and modafinil in a rat model of circadian rhythm and chronic severe fatigue (SLEEP 2023) - "Conclusion This study suggests that the impairment of circadian rhythm induced by a fatigue procedure was reduced to a similar magnitude by modafinil (64 mg/kg) and NLS-4 (16 mg/kg). Since modafinil has been shown to improve recovery from chronic fatigue in human, these results show that NLS-4 could improve recovery from CFS in human at doses four times lower than that used for modafinil."

Preclinical • CNS Disorders • Depression • Pain • Psychiatry

Effects of NLS-4 (lauflumide) and Modafinil in a Rat Model of Chronic Severe Fatigue (ASCP 2023) - "This study suggests that the impairment of circadian rhythm induced by a fatigue procedure was reduced by a similar magnitude with modafinil (64 mg/kg) and NLS-4 (16 mg/kg). Since modafinil has been shown to improve recovery from chronic fatigue in human, these results suggest that NLS-4 could improve recovery from CFS in human at doses four times lower than those used for modafinil. Learning Objectives Describe the specific pharmacology of NLS-4 Describe the process by which NLS-4 is developed"

Preclinical • CNS Disorders • Depression • Pain • Psychiatry

NLS Pharmaceutics CEO Issues Letter to Shareholders (Yahoo Finance) - "...We reported positive pre-clinical data for NLS-4...We intend to advance this compound into clinical development ourselves or with a partner in 2022. As we advance the ongoing Phase 2a trial comparing Quilience to placebo to treat the core symptoms of narcolepsy, we have offered patients the option to roll into a 6-month open label extension (OLE) study, enabling trial participants to remain on Quilience free of charge for an additional half year....We now anticipate reporting interim top-line results for POLARIS in the first quarter of 2022....Activities and events that we anticipate delivering though the end of this year and in 2022 include: final granting of our U.S. patent protecting Quilience's novel once-daily formulation; an investigator presentation at the Wake Up Narcolepsy patient advocacy webinar in November highlighting Quilience and our ongoing Phase 2a clinical program."

New P1 trial • P2a data • Patent • Preclinical • Cataplexy • CNS Disorders • Narcolepsy • Sleep Disorder

NLS Pharmaceutics Ltd. (NLS) Announces Notice of Allowance of two new Patents in North America Covering Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy further bolstering its Patent Portfolio (GlobeNewswire, NLS Pharmaceutics) - U.S. Patent Application No 15/913,481, entitled PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (inventors.. The allowed invention claims a method for treating ADHD with phacetoperane, in particular levophacetoperane, or a pharmaceutically acceptable salt thereof. 'It is hoped that phacetoperane will succeed methylphenidate at least because of its safety profile,' said Eric Konofal, MD, PhD. In addition, Canadian Patent No 2,825,275, entitled LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF (inventor.. The allowed invention claims inventive concepts related to the use of lauflumide or the enantiomers thereof in the treatment of ADHD, narcolepsy or idiopathic hypersomnia.

Clinical • Commercial • Patent